Capula Management’s ImmunityBio IBRX Stock Holding History

Capula Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-104,380	Closed	-$314K	–	744
2025 Q1	$314K	Buy	104,380 +44,279	+74%	+$134K	﹤0.01%	372
2024 Q4	$154K	Buy	+60,101	New	+$250K	﹤0.01%	321

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Capula Management's IBRX Position: Q2 2025 in Review

Capula Management sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 104,380 shares — an estimated $314K sold.

Capula Management first reported a position in IBRX in Q4 2024 and held it in 2 quarters. The position peaked at $314K in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

Capula Management reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
Capula Management sold 104,380 ImmunityBio shares in Q2 2025, an estimated $314K.
Capula Management first reported a position in ImmunityBio in Q4 2024 and held it in 2 quarters.
Capula Management's ImmunityBio position peaked at $314K in Q1 2025.
241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Capula Management's 13F filing for Q2 2025, filed 13 Aug 2025.